Literature DB >> 29322427

Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response.

Ashley S Plant1, Shohei Koyama2, Claire Sinai3, Isaac H Solomon4, Gabriel K Griffin4, Keith L Ligon5, Pratiti Bandopadhayay6, Rebecca Betensky7, Ryan Emerson8, Glenn Dranoff9, Mark W Kieran6, Jerome Ritz10.   

Abstract

There is little known regarding the immune infiltrate present in pediatric brain tumors and how this compares to what is known about histologically similar adult tumors and its correlation with survival. Here, we provide a descriptive analysis of the immune infiltrate of 22 fresh pediatric brain tumor tissue samples of mixed diagnoses and 40 peripheral blood samples. Samples were analyzed using a flow cytometry panel containing markers for immune cell subtypes, costimulatory markers, inhibitory signals, and markers of activation. This was compared to the standard method of immunohistochemistry (IHC) for immune markers for 89 primary pediatric brain tumors. Both flow cytometry and IHC data did not correlate with the grade of tumor or mutational load and IHC data was not significantly associated with survival for either low grade or high grade gliomas. There is a trend towards a more immunosuppressive phenotype in higher grade tumors with more regulatory T cells present in these tumor types. Both PD1 and PDL1 were present in only a small percentage of the tumor infiltrate. T cell receptor sequencing revealed up to 10% clonality of T cells in tumor infiltrates and no significant difference in clonality between low and high grade gliomas. We have shown the immune infiltrate of pediatric brain tumors does not appear to correlate with grade or survival for a small sample of patients. Further research and larger studies are needed to fully understand the interaction of pediatric brain tumors and the immune system.

Entities:  

Keywords:  Flow cytometry; Immune infiltrate; Immunohistochemistry; Immunotherapy; Mutational load; Pediatric brain tumors; T cell receptor

Mesh:

Substances:

Year:  2018        PMID: 29322427     DOI: 10.1007/s11060-017-2737-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  30 in total

Review 1.  Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.

Authors:  Marius Ilie; Véronique Hofman; Manfred Dietel; Jean-Charles Soria; Paul Hofman
Journal:  Virchows Arch       Date:  2016-02-25       Impact factor: 4.064

2.  Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology.

Authors:  Isaac Yang; Seunggu J Han; Michael E Sughrue; Tarik Tihan; Andrew T Parsa
Journal:  J Neurosurg       Date:  2011-06-10       Impact factor: 5.115

3.  Declines in Cancer Death Rates Among Children and Adolescents in the United States, 1999-2014.

Authors:  Sally C Curtin; Arialdi M Minino; Robert N Anderson
Journal:  NCHS Data Brief       Date:  2016-09

4.  Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers.

Authors:  Michael Prosniak; Larry A Harshyne; David W Andrews; Lawrence C Kenyon; Kamila Bedelbaeva; Tatiyana V Apanasovich; Ellen Heber-Katz; Mark T Curtis; Paolo Cotzia; D Craig Hooper
Journal:  Clin Cancer Res       Date:  2013-06-05       Impact factor: 12.531

5.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

6.  Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level.

Authors:  Justyna Kmiecik; Aurélie Poli; Nicolaas H C Brons; Andreas Waha; Geir Egil Eide; Per Øyvind Enger; Jacques Zimmer; Martha Chekenya
Journal:  J Neuroimmunol       Date:  2013-08-31       Impact factor: 3.478

7.  Importance of direct macrophage-tumor cell interaction on progression of human glioma.

Authors:  Yoshihiro Komohara; Hasita Horlad; Koji Ohnishi; Yukio Fujiwara; Bing Bai; Takenobu Nakagawa; Shinya Suzu; Hideo Nakamura; Jun-ichi Kuratsu; Motohiro Takeya
Journal:  Cancer Sci       Date:  2012-10-26       Impact factor: 6.716

Review 8.  Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.

Authors:  Adrian G Sacher; Leena Gandhi
Journal:  JAMA Oncol       Date:  2016-09-01       Impact factor: 31.777

Review 9.  An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.

Authors:  Martha R Neagu; David A Reardon
Journal:  Curr Treat Options Oncol       Date:  2015-11

10.  Immunotherapeutic implications of the immunophenotype of pediatric brain tumors.

Authors:  Andrea M Griesinger; Andrew M Donson; Nicholas K Foreman
Journal:  Oncoimmunology       Date:  2014-01-01       Impact factor: 8.110

View more
  15 in total

1.  Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma.

Authors:  Mark W Kieran; Liliana Goumnerova; Peter Manley; Susan N Chi; Karen J Marcus; Andrea G Manzanera; Maria Lucia Silva Polanco; Brian W Guzik; Estuardo Aguilar-Cordova; C Marcela Diaz-Montero; Arthur J DiPatri; Tadanori Tomita; Rishi Lulla; Lianne Greenspan; Laura K Aguilar; Stewart Goldman
Journal:  Neuro Oncol       Date:  2019-03-18       Impact factor: 12.300

2.  Platelet-derived growth factor beta is a potent inflammatory driver in paediatric high-grade glioma.

Authors:  James L Ross; Zhihong Chen; Cameron J Herting; Yura Grabovska; Frank Szulzewsky; Montserrat Puigdelloses; Lenore Monterroza; Jeffrey Switchenko; Nitin R Wadhwani; Patrick J Cimino; Alan Mackay; Chris Jones; Renee D Read; Tobey J MacDonald; Matthew Schniederjan; Oren J Becher; Dolores Hambardzumyan
Journal:  Brain       Date:  2021-02-12       Impact factor: 13.501

3.  Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma.

Authors:  Soumen Khatua; Laurence J N Cooper; David I Sandberg; Leena Ketonen; Jason M Johnson; Michael E Rytting; Diane D Liu; Heather Meador; Prashant Trikha; Robin J Nakkula; Gregory K Behbehani; Dristhi Ragoonanan; Sumit Gupta; Aikaterini Kotrotsou; Tagwa Idris; Elizabeth J Shpall; Katy Rezvani; Rivka Colen; Wafik Zaky; Dean A Lee; Vidya Gopalakrishnan
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

Review 4.  Immune profiling of pediatric solid tumors.

Authors:  Rachael L Terry; Deborah Meyran; David S Ziegler; Michelle Haber; Paul G Ekert; Joseph A Trapani; Paul J Neeson
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

5.  Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.

Authors:  Nicole A P Lieberman; Kole DeGolier; Heather M Kovar; Amira Davis; Virginia Hoglund; Jeffrey Stevens; Conrad Winter; Gail Deutsch; Scott N Furlan; Nicholas A Vitanza; Sarah E S Leary; Courtney A Crane
Journal:  Neuro Oncol       Date:  2019-01-01       Impact factor: 12.300

Review 6.  Tumour immune landscape of paediatric high-grade gliomas.

Authors:  James L Ross; Jose Velazquez Vega; Ashley Plant; Tobey J MacDonald; Oren J Becher; Dolores Hambardzumyan
Journal:  Brain       Date:  2021-10-22       Impact factor: 13.501

7.  Medulloblastoma recurrence and metastatic spread are independent of colony-stimulating factor 1 receptor signaling and macrophage survival.

Authors:  Erin E Crotty; Stephanie M C Smith; Ken Brasel; Fiona Pakiam; Emily J Girard; Yamicia D Connor; Frederique Zindy; Andrew J Mhyre; Martine F Roussel; James M Olson
Journal:  J Neurooncol       Date:  2021-05-08       Impact factor: 4.506

Review 8.  T lymphocytes as dynamic regulators of glioma pathobiology.

Authors:  Elizabeth C Cordell; Mahmoud S Alghamri; Maria G Castro; David H Gutmann
Journal:  Neuro Oncol       Date:  2022-10-03       Impact factor: 13.029

9.  Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma.

Authors:  Grant L Lin; Surya Nagaraja; Mariella G Filbin; Mario L Suvà; Hannes Vogel; Michelle Monje
Journal:  Acta Neuropathol Commun       Date:  2018-06-28       Impact factor: 7.801

Review 10.  Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.

Authors:  Maria B Garcia-Fabiani; Santiago Haase; Andrea Comba; Stephen Carney; Brandon McClellan; Kaushik Banerjee; Mahmoud S Alghamri; Faisal Syed; Padma Kadiyala; Felipe J Nunez; Marianela Candolfi; Antonela Asad; Nazareno Gonzalez; Marisa E Aikins; Anna Schwendeman; James J Moon; Pedro R Lowenstein; Maria G Castro
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 5.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.